This positions ER-β/GPER1 agonism as a viable intervention not only for BD, but also for schizophrenia, PTSD, and neurodegenerative conditions—particularly within male subgroups marked by chronic inflammation or monoaminergic instability. The gene discussed is GPER1; the disease is schizophrenia.